Piper Jaffray Companies downgraded shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) from an overweight rating to a neutral rating in a report released on Thursday, November 2nd, MarketBeat.com reports.
Several other analysts also recently weighed in on ZBH. Oppenheimer Holdings, Inc. set a $137.00 target price on Zimmer Biomet Holdings and gave the company a buy rating in a report on Monday, August 14th. BidaskClub downgraded Zimmer Biomet Holdings from a hold rating to a sell rating in a report on Tuesday, August 1st. Canaccord Genuity restated a buy rating and issued a $141.00 price target on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. BMO Capital Markets boosted their price target on Zimmer Biomet Holdings from $136.00 to $140.00 and gave the company an outperform rating in a research report on Friday, July 28th. Finally, Gabelli started coverage on Zimmer Biomet Holdings in a research report on Thursday, August 24th. They issued a buy rating and a $142.00 price target on the stock. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of Hold and a consensus price target of $133.71.
Zimmer Biomet Holdings (ZBH) traded up $1.38 during trading hours on Thursday, reaching $113.56. The company had a trading volume of 1,118,532 shares, compared to its average volume of 1,361,683. The stock has a market capitalization of $22,640.00, a price-to-earnings ratio of 13.83, a PEG ratio of 1.73 and a beta of 1.17. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47. Zimmer Biomet Holdings has a 52-week low of $98.20 and a 52-week high of $133.49.
Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). The business had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.83 billion. Zimmer Biomet Holdings had a return on equity of 16.29% and a net margin of 8.36%. The firm’s quarterly revenue was down .8% on a year-over-year basis. During the same period last year, the firm earned $1.79 earnings per share. equities analysts anticipate that Zimmer Biomet Holdings will post 8.03 earnings per share for the current fiscal year.
WARNING: “Zimmer Biomet Holdings, Inc. (ZBH) Rating Lowered to Neutral at Piper Jaffray Companies” was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://baseballnewssource.com/markets/piper-jaffray-companies-downgrades-zimmer-biomet-holdings-inc-zbh-to-neutral/1751107.html.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Ingalls & Snyder LLC increased its holdings in Zimmer Biomet Holdings by 2.6% in the 3rd quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock valued at $2,304,000 after purchasing an additional 507 shares in the last quarter. Koch Industries Inc. grew its stake in shares of Zimmer Biomet Holdings by 49,697.3% during the second quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock valued at $1,033,000 after acquiring an additional 1,038,674 shares in the last quarter. Caxton Associates LP acquired a new stake in shares of Zimmer Biomet Holdings during the first quarter valued at about $403,000. Jensen Investment Management Inc. grew its stake in shares of Zimmer Biomet Holdings by 24.2% during the second quarter. Jensen Investment Management Inc. now owns 5,850 shares of the medical equipment provider’s stock valued at $751,000 after acquiring an additional 1,140 shares in the last quarter. Finally, Andra AP fonden grew its stake in shares of Zimmer Biomet Holdings by 15.8% during the second quarter. Andra AP fonden now owns 21,300 shares of the medical equipment provider’s stock valued at $2,735,000 after acquiring an additional 2,900 shares in the last quarter. Hedge funds and other institutional investors own 85.36% of the company’s stock.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with our FREE daily email newsletter.